We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Umberto Vitolo is a Haematology Consultant, Candiolo Cancer Institute, Fondazione del Piemonte per l’Oncologia, IRCCS, Candiolo (Torino), Italy. His research interests are haematological malignancies, primarily lymphoma. He is a member of the Italian Society of Haematology, the Italian Society of Experimental Haematology and the American Society of Haematology. He has authored many papers in peer-reviewed […]
Professor Jorge Cortes (Georgia Cancer Center, GA, USA) discusses the results from a recent clinical trial that were presented at ASH 2022. Abstract 2757: ‘Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial‘ Disclosures: Jorge Cortes is a […]
Professor Jorge Cortes (Georgia Cancer Center, GA, USA) discusses some of the most interesting abstracts presented at the recent ASH 2022 congress that show advances in triplet therapy for relapsed or refractory acute myeloid leukaemia. Abstracts discussed: Abstract 61: ‘Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with […]
Professor Jorge Cortes (Georgia Cancer Center, GA, USA) discusses his highlights from the recent ASH 2022 conference, including two new agents that look promising in early studies on patients with relapsed or refractory acute myeloid leukaemia. Abstracts discussed: Abstract 63: ‘The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or […]
Momelotinib, an oral JAK1/JAK2/ACVR1 inhibitor, was evaluated in 3 randomised controlled trials – SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM, in patients with high- and intermediate-risk myelofibrosis. In this touchONCOLOGY interview, we speak with Prof. Srdan Verstovsek (MD Anderson Cancer Center, Houston, TX, USA) to discuss the limitations of JAK inhibitor therapy in myelofibrosis, and the integrated analysis of […]
The PACIFICA study aimed to assess the efficacy and safety of pacritinib versus physician’s choice therapy in patients with myelofibrosis and severe thrombocytopenia. In this touchONCOLOGY interview, we speak with Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, New York, NY, USA) to discuss the aims, design and eligibility criteria of the PACIFICA […]
Treatment options for myelofibrosis and severe thrombocytopenia are restricted due to high occurrences of JAK inhibitor-related thrombocytopenia. Pacritinib offers benefits for those patients with cytopenias. In this touchONCOLOGY interview, we speak with Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, New York, NY, USA) to discuss the challenges in the treatment of patients […]
The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]
The SERENA-2 trial (NCT04214288) is a randomised, multicentre phase II trial evaluating camizestrant at several dose levels compared to fulvestrant in advanced ER-positive, HER2-negative breast cancer. In this touchONCOLOGY interview, we speak with Dr Mafalda Oliveira (Vall d’Hebron University Hospital Barcelona, Spain) who gives an overview of the SERENA-2 trial and the advantages for the use […]
Get the latest clinical insights from touchONCOLOGY